Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Ankylosing Spondylitis (BUILDER-1)
NCT01209702Phase 3Terminated
- Sponsor
- Roche
- Start
- Sep 2010
- Primary completion
- May 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 18
01
Overview
A Phase 3 trial of tocilizumab in ankylosing spondylitis (AS), sponsored by Roche. Started Sep 2010; status: terminated.
02
Drugs
tocilizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01209702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01209702.